Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Ichnos Glenmark Innovation Files US FDA Application for Solid Tumour Drug ISB 2301

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Ichnos Glenmark Innovation Files US FDA Application for Solid Tumour Drug ISB 2301

Analysed 18 Nov 2026·2 sources analysed·Hyderabad, India·Business
Ichnos Glenmark Innovation Files US FDA Application for Solid Tumour Drug ISB 2301PreviousNext

Ichnos Glenmark Innovation (IGI), a joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, has submitted an investigational new drug application to the US FDA for ISB 2301, a first-in-class pentaspecific cancer immunotherapy targeting solid tumours. The drug aims to activate T cells and natural killer cells while targeting three tumour-associated antigens to overcome tumour diversity and immune suppression. IGI plans to start Phase I clinical trials in 2027, pending regulatory approval, following promising preclinical results.

Sentiment
72%
TBN's observations

First-hand measurement across 2 sources

We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 42/100.

Outlets measured: moneycontrol, businessstandard. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 18 Nov 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Positive (72/100)

Sentiment was consistent across outlets (70–75/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

businessstandard broke this story on 17 Nov, 04:08 pm. Other outlets followed.

17 Nov, 04:08 pm2 sources · 11 h18 Nov, 03:06 am
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
SpiceJet Flight Delays Leave Hundreds Stranded at Mumbai Airport Amid Operational Issues
Next →
Zepto Rebuilt Packer App Overnight After Crash on Series C Funding Day
1
businessstandard17 Nov, 04:08 pm
Ichnos Glenmark files US FDA application for solid tumour drug ISB 2301
  • 2
    moneycontrol18 Nov, 03:06 am
    Glenmark's IGI files USFDA application for first-in-class solid tumour therapy- Moneycontrol.com
  • Who's involved

    Institutions and figures named across source coverage.

    Government
    United States Food and Drug Administration
    Corporate
    Glenmark PharmaceuticalsGlenmark Pharmaceuticals LimitedAbbVie IncorporatedIchnos SciencesIchnos Glenmark Innovation

    Story context

    Category
    Business
    Location
    Hyderabad, India
    Sources analysed
    2
    Last analysed
    18 Nov 2026
    Key entities
    Food and Drug AdministrationNeoplasmNatural killer cellT cellMoleculeCancerImmune responsePhases of clinical researchBiotechnologyWhite blood cellTolerabilityIndia